Nanobiotix S.A. impresses with several positive study results — stock poised for breakout from base!

Nanobiotix S.A. is a speculative but promising biotechnology company from France. It specializes in the use of nanotechnology in cancer treatments. NBTXR3 is the company's main product and has already been approved in Europe. It aims to expand the benefits of radiation therapy for millions of cancer patients. After about €50 million in revenue this year, there are expectations for a massive increase in revenue to €150 million next year. In mid-September, the company reported good progress in a Phase 1 study with the active ingredient NBTXR3...